Case Report: Use of Liposomal Amphotericin B in Low Doses in Patients With Visceral Leishmaniasis

Background: No consensus has been reached regarding the optimal therapy for visceral leishmaniasis (VL), which affects ~12 million people worldwide.Case Presentation: This report described four cases of VL encountered in the First Affiliated Hospital of Xi'an Jiaotong University between October...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Danfeng Ren, Wenya Cao, Xiaojing Liu, Qunying Han, Wanhu Fan, Guoliang Li, Han Xia, Xi Zhang
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	visceral leishmaniasis (VL) case series amphotericin B (AMB) liposomal amphotericin B (L-AmB) the low-dose L-AmB therapy Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/70ab15800e874ed78577a2321e14521b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:70ab15800e874ed78577a2321e14521b
record_format	dspace
spelling	oai:doaj.org-article:70ab15800e874ed78577a2321e14521b2021-11-17T05:37:34ZCase Report: Use of Liposomal Amphotericin B in Low Doses in Patients With Visceral Leishmaniasis2296-858X10.3389/fmed.2021.766400https://doaj.org/article/70ab15800e874ed78577a2321e14521b2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fmed.2021.766400/fullhttps://doaj.org/toc/2296-858XBackground: No consensus has been reached regarding the optimal therapy for visceral leishmaniasis (VL), which affects ~12 million people worldwide.Case Presentation: This report described four cases of VL encountered in the First Affiliated Hospital of Xi'an Jiaotong University between October 2019 and December 2020. Of the four patients, one patient experienced relapse after antimonial treatment, and the remaining patients had primary VL (including one patient with impaired kidney function and one patient with hemophagocytic syndrome). All patients received a novel treatment protocol, namely the low-dose L-AmB therapy, which was characterized by a low initial dose, cautious dose escalation, and low-dose therapy as maintenance. All patients were cured without severe complications, and there was no further recurrence during follow-up.Conclusions: This case series demonstrated the safety and efficacy of the low-dose L-AmB therapy for VL patients, providing novel treatment protocol for the VL.Danfeng RenWenya CaoXiaojing LiuQunying HanWanhu FanGuoliang LiHan XiaXi ZhangFrontiers Media S.A.articlevisceral leishmaniasis (VL)case seriesamphotericin B (AMB)liposomal amphotericin B (L-AmB)the low-dose L-AmB therapyMedicine (General)R5-920ENFrontiers in Medicine, Vol 8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	visceral leishmaniasis (VL) case series amphotericin B (AMB) liposomal amphotericin B (L-AmB) the low-dose L-AmB therapy Medicine (General) R5-920
spellingShingle	visceral leishmaniasis (VL) case series amphotericin B (AMB) liposomal amphotericin B (L-AmB) the low-dose L-AmB therapy Medicine (General) R5-920 Danfeng Ren Wenya Cao Xiaojing Liu Qunying Han Wanhu Fan Guoliang Li Han Xia Xi Zhang Case Report: Use of Liposomal Amphotericin B in Low Doses in Patients With Visceral Leishmaniasis
description	Background: No consensus has been reached regarding the optimal therapy for visceral leishmaniasis (VL), which affects ~12 million people worldwide.Case Presentation: This report described four cases of VL encountered in the First Affiliated Hospital of Xi'an Jiaotong University between October 2019 and December 2020. Of the four patients, one patient experienced relapse after antimonial treatment, and the remaining patients had primary VL (including one patient with impaired kidney function and one patient with hemophagocytic syndrome). All patients received a novel treatment protocol, namely the low-dose L-AmB therapy, which was characterized by a low initial dose, cautious dose escalation, and low-dose therapy as maintenance. All patients were cured without severe complications, and there was no further recurrence during follow-up.Conclusions: This case series demonstrated the safety and efficacy of the low-dose L-AmB therapy for VL patients, providing novel treatment protocol for the VL.
format	article
author	Danfeng Ren Wenya Cao Xiaojing Liu Qunying Han Wanhu Fan Guoliang Li Han Xia Xi Zhang
author_facet	Danfeng Ren Wenya Cao Xiaojing Liu Qunying Han Wanhu Fan Guoliang Li Han Xia Xi Zhang
author_sort	Danfeng Ren
title	Case Report: Use of Liposomal Amphotericin B in Low Doses in Patients With Visceral Leishmaniasis
title_short	Case Report: Use of Liposomal Amphotericin B in Low Doses in Patients With Visceral Leishmaniasis
title_full	Case Report: Use of Liposomal Amphotericin B in Low Doses in Patients With Visceral Leishmaniasis
title_fullStr	Case Report: Use of Liposomal Amphotericin B in Low Doses in Patients With Visceral Leishmaniasis
title_full_unstemmed	Case Report: Use of Liposomal Amphotericin B in Low Doses in Patients With Visceral Leishmaniasis
title_sort	case report: use of liposomal amphotericin b in low doses in patients with visceral leishmaniasis
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/70ab15800e874ed78577a2321e14521b
work_keys_str_mv	AT danfengren casereportuseofliposomalamphotericinbinlowdosesinpatientswithvisceralleishmaniasis AT wenyacao casereportuseofliposomalamphotericinbinlowdosesinpatientswithvisceralleishmaniasis AT xiaojingliu casereportuseofliposomalamphotericinbinlowdosesinpatientswithvisceralleishmaniasis AT qunyinghan casereportuseofliposomalamphotericinbinlowdosesinpatientswithvisceralleishmaniasis AT wanhufan casereportuseofliposomalamphotericinbinlowdosesinpatientswithvisceralleishmaniasis AT guoliangli casereportuseofliposomalamphotericinbinlowdosesinpatientswithvisceralleishmaniasis AT hanxia casereportuseofliposomalamphotericinbinlowdosesinpatientswithvisceralleishmaniasis AT xizhang casereportuseofliposomalamphotericinbinlowdosesinpatientswithvisceralleishmaniasis
_version_	1718425865806675968

Case Report: Use of Liposomal Amphotericin B in Low Doses in Patients With Visceral Leishmaniasis

Ejemplares similares